Columnists

What’s next for high-tech nappy maker Simavita

October 8, 2018October 8, 2018 | Tim Boreham

HEAR IT FIRST WITH OUR DAILY NEWSLETTER

Email Lists
Morning Update
Lunch Update

Subscribe

We don't spam. Learn more about our Privacy Policy

Columnists

Tim Boreham: here are a dozen ASX stocks that show sport and drugs do mix

October 1, 2018October 1, 2018 | Tim Boreham

Columnists

What’s next for high-flying dodgy knee fixer Paradigm Biopharma

September 24, 2018September 24, 2018 | Tim Boreham

Columnists

Why this ASX cannabis stock is actually turning a profit

September 17, 2018September 17, 2018 | Tim Boreham

Columnists

Why Botanix could be the cannabis tortise that won the race

September 10, 2018September 10, 2018 | Tim Boreham

Columnists

What’s next for Australia’s biggest cannabis stock

September 3, 2018September 3, 2018 | Tim Boreham

Columnists

What’s next for lens maker Visioneering after $12m capital raising

August 29, 2018August 29, 2018 | Tim Boreham

Columnists

Is Anatara good value after 40pc share price drop?

August 20, 2018August 20, 2018 | Tim Boreham

Columnists

Tim Boreham: why kidney disease fighter Dimerix is well worth watching

August 13, 2018August 13, 2018 | Tim Boreham

Columnists

What’s next for IDT Australia after moving away from generic drugs

August 6, 2018August 6, 2018 | Tim Boreham